Avacta Group PLC
LSE:AVCT
Intrinsic Value
Avacta Group Plc engages in the provision of Affimer reagents for licensing into third-party research and diagnostic products, and creates new Affimer medicines for development in-house and licensing... [ Read More ]
The intrinsic value of one AVCT stock under the Base Case scenario is 63.54 GBX. Compared to the current market price of 48.5 GBX, Avacta Group PLC is Undervalued by 24%.
Valuation Backtest
Avacta Group PLC
Run backtest to discover the historical profit from buying and selling AVCT stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Avacta Group PLC
Current Assets | 40.8m |
Cash & Short-Term Investments | 26m |
Receivables | 11.7m |
Other Current Assets | 3.1m |
Non-Current Assets | 47m |
Long-Term Investments | 4.5m |
PP&E | 9m |
Intangibles | 33.5m |
Current Liabilities | 57.1m |
Accounts Payable | 10.8m |
Short-Term Debt | 44.6m |
Other Current Liabilities | 1.7m |
Non-Current Liabilities | 7.9m |
Long-Term Debt | 4.9m |
Other Non-Current Liabilities | 3m |
Earnings Waterfall
Avacta Group PLC
Revenue
|
16m
GBP
|
Cost of Revenue
|
-7.3m
GBP
|
Gross Profit
|
8.7m
GBP
|
Operating Expenses
|
-36.4m
GBP
|
Operating Income
|
-27.7m
GBP
|
Other Expenses
|
-15.1m
GBP
|
Net Income
|
-42.8m
GBP
|
Free Cash Flow Analysis
Avacta Group PLC
What is Free Cash Flow?
AVCT Profitability Score
Profitability Due Diligence
Avacta Group PLC's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
Score
Avacta Group PLC's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
AVCT Solvency Score
Solvency Due Diligence
Avacta Group PLC's solvency score is 30/100. The higher the solvency score, the more solvent the company is.
Score
Avacta Group PLC's solvency score is 30/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AVCT Price Targets Summary
Avacta Group PLC
According to Wall Street analysts, the average 1-year price target for AVCT is 94.18 GBX with a low forecast of 70.7 GBX and a high forecast of 110.25 GBX.
Shareholder Return
AVCT Price
Avacta Group PLC
Average Annual Return | 128.69% |
Standard Deviation of Annual Returns | 287.94% |
Max Drawdown | -85% |
Market Capitalization | 168.2m GBX |
Shares Outstanding | 346 710 137 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Avacta Group Plc engages in the provision of Affimer reagents for licensing into third-party research and diagnostic products, and creates new Affimer medicines for development in-house and licensing to large pharmaceutical companies. The company is headquartered in Wetherby, West Yorkshire. The company went IPO on 2003-09-08. The firm is focused on developing cancer immunotherapies and diagnostics based on its Affimer and prelCISION platforms. The company has two divisions: Therapeutics and Diagnostics. Avacta’s therapeutics division develops cancer immunotherapies combining its platforms: Affimer biotherapeutics and prelCISION tumor targeted chemotherapy. The Affimer platform is a class of biotherapeutic based on a naturally occurring human protein. Avacta's prelCISION targeted chemotherapy platform releases active chemotherapy in the tumor, which limits the systemic exposure that causes damage to healthy tissues, and thereby improves the overall safety and therapeutic potential of these anti-cancer treatments. Avacta’s diagnostics division utilizes its Affimer platform to develop diagnostics and works with partners world-wide to develop Affimer reagents with the objective of establishing royalty-bearing license deals.
Contact
IPO
Employees
Officers
The intrinsic value of one AVCT stock under the Base Case scenario is 63.54 GBX.
Compared to the current market price of 48.5 GBX, Avacta Group PLC is Undervalued by 24%.